Yi-Long Wu

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  

Yi-Long Wu
Aug 24, 2024, 20:21 | Insight
Hidehito Horinouchi summarizes some abstracts of WCLC24 part 3
Hidehito Horinouchi shared on X: Advancing Multimodal Therapies in Stage III NSCLC Chairs: Feng-Ming Spring Kong,…
Aug 14, 2024, 01:53 | Insight
5 papers about lung cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Aug 6, 2024, 06:07 | Insight
Primary analysis of the phase 2 INSIGHT 2 study of tepotinib combined with osimertinib
Lungevity Foundation shared a recent article by Yi-Long Wu, commenting: "What's after osimertinib for pts…
Aug 5, 2024, 01:55 | Societies
Scientific Committees at the ESMO Congress 2024
The ESMO Congress is a globally influential oncology platform that brings together clinicians, researchers, patient…
Jul 30, 2024, 13:41 | Insight
Brendon Stiles: Neoadjuvant chemo-ICI in marginally resectable patients
Brendon Stiles, Professor and Chief of Thoracic Surgery and Surgical Oncology at Montefiore Health System,…
Jul 30, 2024, 06:39 | Insight
Ph II KUPENG trial of Vebreltinib in Advanced MetExon14 and NSCLC
Jarushka Naidoo shared a post on X about a recent paper by Jin-Ji Yang et…
Jul 27, 2024, 14:16 | Insight
Foritinib in advanced ROS1-rearranged NSCLC in China
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a…
Jul 16, 2024, 13:55 | Blog
5 papers to read suggested by Vivek Subbiah
We are presenting articles suggested by Vivek Subbiah: 1.'Pancreatic Cancer Surveillance and Survival of High-Risk…
May 19, 2024, 05:07 | Drugs
First prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced NSCLC - Top Science
Top Science shared on X: “This is the first prospective phase 2 study to directly…
May 7, 2024, 15:08 | Blog
Stephen Liu: Dr. Yi-Long Wu discusses adjuvant EGFR targeted therapy at RomeLung24
Stephen Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University, shared on X/Twitter: "Dr.…
May 3, 2024, 20:15 | Opinion
Brendon Stiles: Great presentation from Dr. Wu on ALINA
Brendon Stiles, Professor and Chief of Thoracic Surgery and Surgical Oncology at Montefiore Health System,…
Apr 26, 2024, 20:26 | Insight
New Paper Alert! Liposomal Irinotecan vs Topotecan for Relapsed Small Cell Lung Cancer: RESILIENT Phase 3 Trial
Liposomal Irinotecan vs Topotecan for Relapsed Small Cell Lung Cancer: RESILIENT Phase 3 Trial Authors:…
Apr 23, 2024, 23:18 | Insight
Karan Sood: A much needed asian perspective on thoracic oncology
Karan Sood, Medical Oncology Resident at Jawaharlal Nehru Medical College, shared on X: “In company…
Apr 19, 2024, 15:52 | Drugs
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on ALINA trial
FDA, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following…
Oct 23, 2023, 15:35 | Blog
Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT
Julien Mazières, Thoracic Oncology Specialist at Toulouse University Hospital, France, shared insights from the ALINA…
All: 15 Posts: 1 - 100
Special Coverage